Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Common Equity (2016 - 2026)

Integra Lifesciences Holdings' Common Equity history spans 17 years, with the latest figure at $1.0 billion for Q4 2025.

  • On a quarterly basis, Common Equity fell 32.47% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 32.47% decrease, with the full-year FY2025 number at $1.0 billion, down 32.47% from a year prior.
  • Common Equity hit $1.0 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.0 billion in the prior quarter.
  • Over the last five years, Common Equity for IART hit a ceiling of $1.8 billion in Q4 2022 and a floor of $1.0 billion in Q3 2025.
  • Historically, Common Equity has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in Common Equity: rose 16.74% in 2021 and later tumbled 32.47% in 2025.
  • Tracing IART's Common Equity over 5 years: stood at $1.7 billion in 2021, then increased by 7.1% to $1.8 billion in 2022, then fell by 12.0% to $1.6 billion in 2023, then dropped by 2.68% to $1.5 billion in 2024, then tumbled by 32.47% to $1.0 billion in 2025.
  • Business Quant data shows Common Equity for IART at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.